Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes

Circulation

Volumn 104, Issue 23, 2001, Pages 2767-2771

  Roffi, Marco ^a   Chew, Derek P ^a   Mukherjee, Debabrata ^b   Bhatt, Deepak L ^a   White, Jennifer A ^a   Heeschen, Christopher ^c   Hamm, Christian W ^d   Moliterno, David J ^a   Califf, Robert M ^e   White, Harvey D ^f   Kleiman, Neal S ^g   Théroux, Pierre ^h   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d KERCKHOFF HEART CENTER   (Germany)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f GREEN LANE HOSPITAL   (New Zealand)

^g HOUSTON METHODIST HOSPITAL   (United States)

^h MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Angina; Angioplasty; Diabetes mellitus; Glycoproteins; Platelets

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; TIROFIBAN;

ANGINA PECTORIS; ANGIOPLASTY; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; ST SEGMENT ELEVATION; STATISTICAL ANALYSIS; THROMBOCYTE AGGREGATION;

EID: 0035808028     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc4801.100029     Document Type: Article

References (31)

1. Global burden of diabetes. 1995-2025: Prevalence, numerical estimates, and projections
2. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group
3. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries
4. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry
5. Hypersensitivity of diabetic human platelets to platelet activating factor
6. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo: Evidence derived from the study of peripheral arterial disease
7. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
8. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) Study Investigators
9. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network
10. Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: Rationale and design of the PARAGON B study. The PARAGON B International Steering Committee
11. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
12. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: The GUSTO IV-ACS randomised trial
13. George Lyman Duff Memorial Lecture. Atherogenesis in diabetes
14. Morality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
15. Diabetes and atherosclerosis: An epidemiologic view
16. Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients
17. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus
18. Increased aggregation of human platelets produced by advanced glycation end products in vitro
19. Mean platelet volume in diabetes mellitus
20. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus
21. Elevated circulating P-selectin in insulin dependent diabetes mellitus
22. Platelet-leukocyte-cross-talk in diabetes mellitus
23. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects
24. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention
25. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study
26. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: Results of a Veterans Administration Cooperative Study
27. Aspirin, sulfinpyrazone, or both in unstable angina: Results of a Canadian multicenter trial
28. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial. EPISTENT Investigators Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
29. Abciximab reduces mortality in diabetics following percutaneous coronary intervention
30. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators, Platelet Receptor Inhibition in Ischemic Syndrome Management
31. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: The PARAGON-B troponin T substudy